Evidence map›Paper›PMID 39438472›Full record

ArticleNature communications2024

Modeling NK-cell lymphoma in mice reveals its cell-of-origin and microenvironmental changes and identifies therapeutic targets.

Junji Koya, Tomohiko Tanigawa, Kota Mizuno, Haryoon Kim, Yuta Ito, Mitsuhiro Yuasa, Kentaro Yamaguchi, Yasunori Kogure, Yuki Saito, Sumito Shingaki and 20 more

Abstract read
In one paragraph

Article in Nature communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Review
  5. Review
  6. Molecular pathogenesis and evolving treatment landscape of extranodal NK/T-cell lymphoma.Proceedings of the Japan Academy. Series B, Physical and biological sciences · 2026
    Review
  7. Article
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

30 authors.

Junji Koya *Division of Molecular Oncology, National Cancer Center Research Institute, Tokyo, Japan.ORCID 0000-0002-0605-1226
Tomohiko Tanigawa *Division of Molecular Oncology, National Cancer Center Research Institute, Tokyo, Japan.
Kota MizunoDivision of Molecular Oncology, National Cancer Center Research Institute, Tokyo, Japan.ORCID 0000-0001-6090-0260
Haryoon KimDivision of Molecular Oncology, National Cancer Center Research Institute, Tokyo, Japan.
Yuta ItoDivision of Molecular Oncology, National Cancer Center Research Institute, Tokyo, Japan.ORCID 0000-0001-7259-4870
Mitsuhiro YuasaDivision of Molecular Oncology, National Cancer Center Research Institute, Tokyo, Japan.
Kentaro YamaguchiDivision of Molecular Oncology, National Cancer Center Research Institute, Tokyo, Japan.
Yasunori KogureDivision of Molecular Oncology, National Cancer Center Research Institute, Tokyo, Japan.
Yuki SaitoDivision of Molecular Oncology, National Cancer Center Research Institute, Tokyo, Japan.ORCID 0000-0003-2686-9604
Sumito ShingakiDivision of Molecular Oncology, National Cancer Center Research Institute, Tokyo, Japan.
Mariko TabataDivision of Molecular Oncology, National Cancer Center Research Institute, Tokyo, Japan.
Koichi MurakamiDivision of Molecular Oncology, National Cancer Center Research Institute, Tokyo, Japan.
Kenichi ChibaDivision of Genome Analysis Platform Development, National Cancer Center Research Institute, Tokyo, Japan.
Ai OkadaDivision of Genome Analysis Platform Development, National Cancer Center Research Institute, Tokyo, Japan.
Yuichi ShiraishiDivision of Genome Analysis Platform Development, National Cancer Center Research Institute, Tokyo, Japan.ORCID 0000-0001-6144-5845
Amira MaroufLaboratory of cellular and molecular mechanisms of hematological disorders and therapeutic implications, INSERM UMR_S 1163, Imagine Institute, Université Paris Cité, Paris, France.
Raphaël LiévinLaboratory of cellular and molecular mechanisms of hematological disorders and therapeutic implications, INSERM UMR_S 1163, Imagine Institute, Université Paris Cité, Paris, France.
Sammara ChaubardHematology department, Limoges University Hospital, Limoges, France.
Arnaud JaccardHematology department, Limoges University Hospital, Limoges, France.
Olivier HermineLaboratory of cellular and molecular mechanisms of hematological disorders and therapeutic implications, INSERM UMR_S 1163, Imagine Institute, Université Paris Cité, Paris, France.
Laurence de LevalInstitute of Pathology, Department of Laboratory Medicine and Pathology, Lausanne University Hospital and Lausanne University, Lausanne, Switzerland.ORCID 0000-0003-3994-516X
Olivier TournilhacDepartment of Hematology, Clermont-Ferrand University Hospital, Clermont Auvergne University, Clermont-Ferrand, France.ORCID 0000-0002-9438-621X
Gandhi DamajDepartment of Hematology, Caen University Hospital, Normandy University, Caen, France.ORCID 0000-0002-4689-3882
Philippe GaulardUniversity Paris Est Créteil, INSERMU955, IMRB, Créteil, France.
Lucile CouronnéLaboratory of cellular and molecular mechanisms of hematological disorders and therapeutic implications, INSERM UMR_S 1163, Imagine Institute, Université Paris Cité, Paris, France.
Teruhito YasuiLaboratory of Infectious Diseases and Immunity, Microbial Research Center for Health and Medicine, National Institutes of Biomedical Innovation, Health and Nutrition, Ibaraki City, Japan.
Kazutaka NakashimaDivision of Pathology, Kurume University, Fukuoka, Japan.
Hiroaki MiyoshiDivision of Pathology, Kurume University, Fukuoka, Japan.ORCID 0000-0002-2356-3725
Koichi OhshimaDivision of Pathology, Kurume University, Fukuoka, Japan.
Keisuke KataokaDivision of Molecular Oncology, National Cancer Center Research Institute, Tokyo, Japan. kkataoka-tky@umin.ac.jp.ORCID 0000-0002-8263-9902

Funding

Japan Agency for Medical Research and Development (AMED) JP20ck0106442Japan Agency for Medical Research and Development (AMED) JP23gm1810002MEXT | Japan Science and Technology Agency (JST) JPMJMS2022MEXT | Japan Society for the Promotion of Science (JSPS) 22H03108MEXT | Japan Society for the Promotion of Science (JSPS) JP21H05051Princess Takamatsu Cancer Research Fund NATakeda Science Foundation NA
6 · The paper itself

Abstract

Extranodal NK/T-cell lymphoma (ENKTCL) is an Epstein-Barr virus (EBV)-related neoplasm preferentially involving the upper aerodigestive tract. Here we show that NK-cell-specific Trp53 disruption in mice leads to the development of NK-cell lymphomas after long latency, which involve not only the hematopoietic system but also the salivary glands. Before tumor onset, Trp53 knockout causes extensive gene expression changes, resulting in immature NK-cell expansion, exclusively in the salivary glands. Both human and murine NK-cell lymphomas express tissue-resident markers, suggesting tissue-resident NK cells as their cell-of-origin. Murine NK-cell lymphomas show recurrent Myc amplifications and upregulation of MYC target gene signatures. EBV-encoded latent membrane protein 1 expression accelerates NK-cell lymphomagenesis and causes diverse microenvironmental changes, particularly myeloid propagation, through interferon-γ signaling. In turn, myeloid cells support tumor cells via CXCL16-CXCR6 signaling and its inhibition is effective against NK-cell tumors in vivo. Remarkably, KLRG1-expressing cells expand in the tumor and are capable of repopulating tumors in secondary recipients. Furthermore, targeting KLRG1 alone or combined with MYC inhibition using an eIF4 inhibitor is effective against NK-cell tumors. Therefore, our observations provide insights into the pathogenesis and highlight potential therapeutic targets, including CXCL16, KLRG1, and MYC, in ENKTCL, which can help improve its diagnostic and therapeutic strategies.

Indexed as

Killer Cells, NaturalLymphoma, Extranodal NK-T-CellProto-Oncogene Proteins c-mycTumor MicroenvironmentTumor Suppressor Protein p53AnimalsCell Line, TumorChemokine CXCL16Disease Models, AnimalGene Expression Regulation, NeoplasticHerpesvirus 4, HumanHumansInterferon-gammaMiceMice, Inbred C57BLMice, KnockoutChemokine CXCL16Interferon-gammaMyc protein, mouseProto-Oncogene Proteins c-mycReceptors, CXCR6Trp53 protein, mouseTumor Suppressor Protein p53

Identifiers

PMID39438472
PMCPMC11496546

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.